Business Wire

Pharnext to Present Latest Scientific Data on its Two Lead Assets at Several International Scientific Conferences

Jaa

Regulatory News:

Pharnext SA (FR0011191287 - ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced its upcoming participation in five international scientific conferences in June and July 2018 throughout Europe and the United States.

Pharnext will share the latest scientific and clinical data regarding PXT3003, a drug candidate which is currently being evaluated in an ongoing international pivotal Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A. Pharnext will also illustrate the benefits of its disruptive R&D approach PLEOTHERAPY™ in developing drug combinations, and discuss the Company’s Phase 2 trial of PXT864 for the treatment of Alzheimer’s disease.

The company will attend the following events:

European Academy of Neurology (EAN) congress
June 16-18, 2018 in Lisbon, Portugal

Two ePosters (oral communications)

#EPR1170  

A multicenter, double-blind, placebo-controlled, pivotal phase III study (PLEO-CMT) of a
fixed combination of baclofen, naltrexone and sorbitol (PXT3003) for Charcot-Marie-Tooth
Disease Type 1A (CMT1A).

Presenter:   Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Room   Session EPR122 / Screen B12
Date/Time   June 16, 2018, 13:30 - 14:15 CEST
#EPR1007  

Double-blind argument for a synergistic therapeutic effect of a fixed low-dose combination
of acamprosate and baclofen in Alzheimer's disease.

Presenter:   Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Room   Session EPR101 / Screen A1
Date/Time   June 16, 2018, 13:30 - 14:15 CEST

International Congress on Neuromuscular Diseases (ICNMD)
July 6-10, 2018 in Vienna, Austria

Two Posters

#545   Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats.
Authors   T. Prukop et al.
Room   Mezzanine Floor Gallery and Foyers
Date/Time   July 8, 2018, 5:15pm - 6:30pm CEST
#728  

Baclofen, naltrexone and sorbitol all contribute to PXT3003-induced myelination in CMT1A
DRG co-cultures.

Authors   N. Cholet et al.
Room   Session Room 1
Date/Time   July 8, 2018, 5:15pm - 6:30pm CEST

Innovations and State of the Art In Dementia Research meeting (ISADR)
July 16-18, 2081 in Valencia, Spain

Two Oral Communications

   

Cmax-based synergistic therapeutic effect on cognitive disability in mild Alzheimer’s
disease after 36 weeks treatment with baclofen and acamprosate.

Presenter:   Prof Jacques Touchon, MD, PhD, Faculteì de Meìdecine de Montpellier, France
Date/Time   July 16, 2018, 11:35am - 11:55am CEST
    A potential tri-therapy for Alzheimer’s disease.
Presenter:   Dr Rodolphe Hajj, PhD, Chief Pharmacology Officer, Pharnext, France
Date/Time   July 16, 2018, 12:55pm - 1:15pm CEST

Peripheral Nerve Society (PNS) congress
July 22-25, 2018 in Baltimore, US

One Oral Communication

   

Status of the Pivotal Phase III Study of PXT3003 for Charcot-Marie-Tooth Type 1A disease
(CMT1A).

Presenter:   Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Date/Time   July 23, 2018, 2.45pm - 3.00pm EST

Four Posters

#20   Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats.
Authors   R. Hajj et al.
Session   Session 1
Date/Time   July 22, 2018
#45  

Status of the Pivotal Phase III Study of PXT3003 for Charcot-Marie-Tooth Type 1A disease
(CMT1A)

Authors   R. Goedkoop et al.
Session   Session 2
Date/Time   July 23, 2018
#85  

Synergy of baclofen, naltrexone and sorbitol (PXT3003) in Charcot-Marie-Tooth Type 1A
(CMT1A)

Authors   J. Laffaire et al
Session   Session 2
Date/Time   July 23, 2018
#1

Baclofen, naltrexone and sorbitol all contribute to PXT3003-induced myelination in CMT1A
DRG co-cultures

Authors R. Hajj et al.
Session Session 3
Date/Time July 24, 2018

Alzheimer's Association International Conference (AAIC)
July 22-26, 2018 in Chicago, US

Two Posters

#P1-061  

Double-blind argument for a synergistic therapeutic effect of a fixed low-dose combination
of acamprosate and baclofen in Alzheimer’s Disease

Authors   J-M Orgogozo et al
Session   Session P1-01 / Hall F1
Date/Time   July 22, 2018, 9:30am - 4:15pm EST
#P3-042  

PXT864 combination restores cognitive deficits of Alzheimer’s mice, even in animals with
advanced disease that lost responsiveness to donepezil.

Authors   A. Brureau et al.
Session   Session P3-02, Hall F1
Date/Time   July 24, 2018, 9:30am - 4:15pm EST

If you are interested in meeting the Pharnext team during either of these events or if you need more information about Pharnext’s participation, please send an email to contact@pharnext.com

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit http://www.pharnext.com/

Contact information

Pharnext
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
contact@pharnext.com
or
Financial Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1 56 88 11 15
sruiz@actifin.fr
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
matthew@sternir.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Media Relations (Europe)
Ulysse Communication
Bruno Arabian, +33 (0)1 81 70 96 30
barabian@ulysse-communication.com
or
Media Relations (U.S.)
RooneyPartners
Kate L. Barrette, +1 212 223 0561
kbarrette@rooneyco.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

ABB and Kawasaki Create World’s First Common Interface for Collaborative Robots20.6.2018 14:00Tiedote

ABB and Kawasaki Heavy Industries, both global leading players in industrial automation and robotics, are showcasing the world’s first common collaborative robot operating interface at automatica in Munich, Germany from June 19-22, 2018. The common interface will also help address the shortage of skilled workers in many industries. In Japan for example, one person in five is within a decade of retirement. Demand for collaborative robots has outpaced the rapidly-growing industrial robot market, as easier-to-use robots open doors to new users. The fact that collaborative robots can be programmed and operated by people without specialized training helps small and medium enterprises, in particular, to leapfrog traditionally longer industrial robot learning curves. Collaborative robots (cobots) that can be operated by nearly any user can help offset labor shortages. Their flexibility to work nearly anywhere in a factory without safety barriers also makes them ideal for meeting sudden and un

CORRECTING and REPLACING Deutsche Bank Moves Reconciliation Services to SmartStream to Further Improve Processing and Reduce Costs20.6.2018 13:38Tiedote

First paragraph, first sentence of release should read: As part of its transformation strategy, Deutsche Bank has selected SmartStream ... (instead of 'As part of a wider strategy to adopt industry utilities, Deutsche Bank has selected SmartStream ...'). The corrected release reads: DEUTSCHE BANK MOVES RECONCILIATION SERVICES TO SMARTSTREAM TO FURTHER IMPROVE PROCESSING AND REDUCE COSTS As part of its transformation strategy, Deutsche Bank has selected SmartStream Technologies’ Centre of Excellence (CoE) to provide an off-site operations platform - including three services which will allow the bank to streamline, simplify and reduce the costs of its reconciliations environment. With the growth in volume of reconciliations, the processing of large quantities of data has become complex. Many financial institutions are exploring utilities to ensure accuracy and cost savings. With the addition of the CoE to Deutsche Bank, SmartStream will provide the bank with three distinct managed servic

Hotelsclick.com: You Can Pay the Hotel with Amazon Pay20.6.2018 13:32Tiedote

Hotelsclick.com, the Italy-based online booking for hotels, has integrated Amazon Pay into its payment methods, becoming one of the first OTA in Europe offering this service. Besides traditional payment methods, such as credit cards (included Amex) and Paypal, users that book a hotel on Hotelsclick.com and hold an Amazon account can choose Amazon Pay to complete the reservation: they only need to enter their Amazon username and password during the checkout process on Hotelsclick.com and the transaction will be carried out quick and safe. As a matter of fact, making an online reservation will be more and more easy thanks to Amazon Pay. Users will no longer need to enter multiple password or other payment details: all information will be automatically taken from their Amazon account. “We are very proud to bring Amazon Pay to our users who visit us on their PCs and mobile. Customers’ experience is our main concern: adding Amazon Pay we are confident we can consistently improve it, making

UEC Presents Its Latest Solution for Gas Transportation and Power Generation at MIOGE 201820.6.2018 12:55Tiedote

United Engine Corporation of Rostec Corporation takes part in the 15th Moscow International Oil and Gas Exhibition (MIOGE 2018). There it will demonstrate gas turbine gas compressor and power generating sets, which are the most promising on the Russian and foreign markets. UEC's exhibition booth presents layouts of gas pumping unit GPA-16, Katangli power facility, and Novoprivodinskaya compressor station. The companies of Russian fuel and energy complex —Gazprom, NC Rosneft, Lukoil, Surgutneftegas and others — are the main consumers of power and gas pumping units produced by UEC. To date, Gazpom uses around 1,500 industrial engines manufactured by the corporation. UEC is going to increase the share of gas turbine industrial equipment in the total volume of its supplies. The corporation is actively performing its activities aimed at entering foreign markets. In May 2018, UEC introduced its latest developments at the exhibitions Iran Oil Show in Tehran, Oil & Gas Uzbekistan in Tashkent a

Alibaba Group and Kantar Join Forces to Redefine Brand Building at ‘China-Speed’20.6.2018 12:00Tiedote

Kantar and Alibaba Group announced today, during Cannes Lions International Festival of Creativity, the launch of their new partnership to redefine brand building in China by co-creating an integrated ‘insight to activation’ platform that will help CMOs to develop, measure and optimise their marketing activities at ‘China Speed.’ Together, they will help brands realise the vision of ‘real time’ brand and campaign management. Today, marketers of Chinese and global brands alike see their marketing strategies outpaced by the scale, scope and speed of China’s consumer market and media transformation. To address these needs, the first phase of the partnership focused on unifying fragmented brand metrics into a new integrated ‘insight-to-activation’ platform, enabling brands and businesses to make more agile decisions. Kantar mapped and validated Alibaba’s Marketing KPI ‘Consumer Asset’ framework (launched in 2017) to Kantar’s broader portfolio of marketing KPIs. With the validation of the C

AI Expo: What Not to Miss at the AI Expo Europe Next Week Including Female Expert Speakers20.6.2018 12:00Tiedote

Arriving in Amsterdam next week on the 27-28 June, the second annual AI Expo Europe event will be co-hosted with two co-located events covering the IoT and Blockchain ecosystem; IoT Tech Expo & Blockchain Expo. With over 9,000 top-level attendees already registered including CTO’s, CDO’s, Heads of Innovation & Technology, IT Directors, Developers, Start-Up’s, VC’s, OEM’s across a range of industries including but not limited to; Marketing, Automotive, HR & Recruitment, Finance, Insurance, Government, Public Sector, Retail, Industrial, Healthcare, Education, Cyber Security and Developer platforms. The AI Expo will showcase the most cutting-edge technologies from more than 300 exhibitors and provide insight from over 300 speakers sharing their unparalleled industry knowledge, real-life experiences, valuable case studies & dedicated Q&A sessions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180620005048/en/ Leading female AI

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme